Douglas Beall, M.D., chief of radiology services at Clinical Radiology of Oklahoma and principal investigator of the VAST study, will be presenting data from VIVEXās 12-month study of VIA Disc® for ...
MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S.
MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced the publication of a new real-world evidence study demonstrating ...
An injection that relieves low back pain by helping damaged spinal discs regenerate appears to have sustained benefits, new clinical trial data show. Most patients who received an injection of VIA ...
Patients received a single injection of 100 mg of VIA Disc NP, a micronized cadaveric disc tissue product reconstituted with saline. Under fluoroscopic guidance, the product was delivered into ...
MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND ...
First-ever published 12-month results from Level 1 intradiscal study for treating patients with one or two level symptomatic degenerative disc disease Early evidence suggests greater than 70% ...
Analysis of 1,804 Medicare beneficiaries per group demonstrates a meaningful shift in the continuum of care following intradiscal nucleus pulposus allograft procedure MIAMI, June 05, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results